Articles by Sam M

U.S. Patent and Trademark Office (USPTO) Granted Patent on March 25 for Tonic3’s ‘Augmented Reality (AR) Platform’

DALLAS, April 20, 2023 (Newswire.com)
–
Tonic3, a leading provider of Enterprise User Experience and Engineering Solutions, recently announced a milestone. On March 25, the U.S. Patent and Trademark Office (USPTO) granted a patent for its “Augmented Reality (AR) platform.”

The patent covers a unique method of processing augmented reality technology as a platform ecosystem, including specialized experience triggers and multi-device experience synchronization. 

This is Tonic3’s first patent, made possible through the work of its XR Labs, a specialized research and publishing team focused on providing thought leadership and best practices to the extended reality (XR) industry. XR refers to immersive technologies, including virtual reality (VR), augmented reality (AR), and mixed reality. AR is a set of technologies that allow users to visualize part of the real world through a technological device with graphical information added by the user.

“At our XR Labs, we focus on the end-user first by applying techniques and empirical models to create groundbreaking technology applications in augmented reality, virtual reality, artificial intelligence, and other related fields,” said Preston McCauley, Director of Innovation at Tonic3, about this recent and valuable achievement.

Tonic3 has been a leader in technology development for several years and works with clients from many industries. The patent grant reflects part of the company’s future as it combines UX expertise with cutting-edge technology and the ability to fully deliver solutions.

About Tonic3

Tonic3 has been dedicated to humanizing digital connections for over 25 years, through insight-driven solutions in Enterprise UX, Development, and now AR/VR. The company has 100 full-time team members in the United States and Latin America, working with diverse clients across multiple verticals, ranging from Fortune 100 to funded startups.

Tonic3’s XR Labs is a specialized research and publishing team dedicated to bringing thought leadership to the extended reality (XR) industry, as well as recognizing and establishing XR best practices. From neurological and physiological impacts to XR research methodologies and design and coding processes that help deliver real-world XR experiences, XR Labs aims to build and share a knowledge base that encourages the growth of a digitally connected XR future for people around the world.

For more information, please visit www.tonic3.com or follow company news on LinkedIn at https://www.linkedin.com/company/tonic3/.

Contact Information:

Joe Edwards

CEO

[email protected]

214.774.2390

Alejandra Sanchez

Head of Customer Success

[email protected]

214.774.2390

Original Source:

Tonic3 Obtains Patent for Augmented Reality Platform

The post Tonic3 Obtains Patent for Augmented Reality Platform first appeared on Enrose Magazine.

Thirdwave RX, a rebate administration company for healthcare providers, has announced the launch of its new website.

…

The post Thirdwave RX, Healthcare Rebate Administrator, Announces New Website first appeared on Enrose Magazine.

WASHINGTON, April 19, 2023 (Newswire.com)
–
A recently published article in Experimental Biology and Medicine (Volume 248, Issue 3, January, 2023) …

The post New Study in Experimental Biology and Medicine Highlights the Links Between Air Quality and COVID-19 Severity first appeared on Enrose Magazine.

Reducing neuroinflammation with Photobiomodulation

Photobiomodulation Treatment Reversal Solutions Photobiomodulation Treatment
…

The post Photobiomodulation Treatments Are Demonstrating Neuroinflammation Reduction Potential first appeared on Enrose Magazine.

Reducing neuroinflammation with Photobiomodulation

Photobiomodulation Treatment Reversal Solutions Photobiomodulation Treatment
…

The post Photobiomodulation Treatments Are Demonstrating Neuroinflammation Reduction Potential first appeared on Enrose Magazine.

Combination of PacBio’s HiFi Sequencing Capabilities and Form Bio’s Computational Platform and Solutions Helps Biopharma and Academic Researchers Innovate and Accelerates Gene Therapy Product Development

DALLAS, April 19, 2023 (Newswire.com)
–
Form Bio, the provider of advanced computational life sciences technology, today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as compatible with PacBio’s HiFi sequencing solutions, empowering corporate and academic research teams with a dramatically streamlined path from HiFi read data to breakthrough insights.

In particular, AAV-based gene therapy can address the underlying genetic problems that cause disease and holds great promise to help improve human health. With the combination of Form Bio’s data analysis capabilities and PacBio’s sequencing solutions, scientists can enhance their understanding of the genetic components underlying disease and ultimately improve AAV gene therapies in their application to a vast spectrum of diseases.

PacBio is a developer of high-quality, highly accurate sequencing solutions, providing the advantage of being able to sequence entire, intact constructs with high accuracy. The ability to produce full length reads is important for AAV gene therapy discovery and for confirming the quality of these constructs.

By combining PacBio’s HiFi sequencing capabilities with Form Bio’s innovative computational platform and solutions, mutual customers can not only accelerate but also advance and enhance the quality of research that relies on full read data. In addition, the Form Bio platform includes access to an optimized AAV PacBio QC workflow for characterizing the quality of AAV vector manufacturing.

“We’re thrilled to team up with PacBio to help advance gene therapy discovery and development,” said Kent Wakeford, co-CEO for Form Bio. “This partnership brings together our technology and expertise to provide an ‘easy button’ for PacBio customers, who are looking to get the most out of their HiFi sequencing data but face practical constraints with bioinformatics or computational resources.”

“We share Form Bio’s vision to help scientists and gene therapy developers move the industry forward, making this partnership a natural fit,” said Jeff Eidel, chief commercial officer for PacBio. “Form Bio’s powerful platform, advanced AI-based solutions and uniquely strong combination of both life science and data science expertise all add tremendous value to how researchers utilize PacBio products and solutions.”

To learn more about how Form Bio and PacBio solutions work together, visit https://formbio.com/pacbio. 

About Form Bio

Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With an accessible, comprehensive and collaborative platform, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. For more information on Form Bio, visit www.formbio.com

Contact Information:

Maggie Whitney

Senior Public Relations Executive

[email protected]

2039571502

Alison Guzzio

Public Relations Director

[email protected]

4844593243

Original Source:

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

The post Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights first appeared on Enrose Magazine.

New technology will better serve aging and disability communities in Tennessee

NASHVILLE, Tenn., April 18, 2023 (Newswire…

The post Tennessee Commission on Aging and Disability (TCAD) Partners With Mon Ami first appeared on Enrose Magazine.

New technology will better serve aging and disability communities in Tennessee

NASHVILLE, Tenn., April 18, 2023 (Newswire…

The post Tennessee Commission on Aging and Disability (TCAD) Partners With Mon Ami first appeared on Enrose Magazine.

Brightstar Therapeutics Logo

LEXINGTON, Ky., April 18, 2023 (Newswire.com)
–
Brightstar Therapeutics, a biotechnology company focused on providing inno…

The post Brightstar Therapeutics Secures Series A Financing to Propel Groundbreaking Treatment for Corneal Diseases; Appoints Chief Medical Officer and Chief Scientific Officer to Lead first appeared on Enrose Magazine.

SAN DIEGO, April 17, 2023 (Newswire.com)
–
Genome Insight, a leading precision medicine and genomics company, announced that their innovative whole genome sequencing (WGS) approach will be featured in six poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL. These posters cover a range of topics, including a study of integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in hepatocellular carcinoma (HCC), as well as a comparison between whole-genome sequencing-based and targeted panel sequencing approaches to precision oncology.

One notable presentation highlights that Genome Insight’s WGS approach provides a more thorough analysis of genetic mutations in breast cancers with homologous recombination deficiency (HRD) than traditional BRCA gene testing. WGS can accurately classify HR status and identify which patients would benefit from polymerase enzymes (PARP) inhibitor treatment, making it a fast and effective screening tool.

“We are thrilled to present our WGS approach at the AACR annual meeting, which demonstrates the potential of our innovative approach to impact clinical decision-making for patients with cancer.” – Dr. Young Seok Ju, CEO of Genome Insight

For more information about Genome Insight’s WGS approach and other services, visit www.genomeinsight.net.

About Genome Insight 

Genome Insight is a precision medicine whole genome platform company with the goal to accelerate the use of whole genome sequencing (WGS) for accurate diagnosis and personalized treatment for cancer and rare diseases. Genome Insight’s proprietary platform is an automated WGS pipeline coupled with a bioinformatics-powered digital solution that rapidly generates meaningful medical insights, making it possible to use WGS in real-life clinical settings. Furthermore, this platform is applied in the research setting to advance novel therapeutic strategies in cancer and rare diseases. The company’s headquarters is in San Diego (US) with offices in Korea (Seoul and Daejeon) and Hong Kong. To learn more, please visit www.genomeinsight.net

Contact Information:

Steven Esparza

Chief Executive Officer

[email protected]

6193631368

Original Source:

Genome Insight’s Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023

The post Genome Insight’s Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023 first appeared on Enrose Magazine.